CoChat

A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia

Open access
Lam, Stephen, Mandrekar, Sumithra J., Gesthalter, Yaron, Allen Ziegler, Katie L., Seisler, Drew K., Midthun, David E., Mao, Jenny T., Aubry, Marie Christine, McWilliams, Annette, Sin, Don D., Shaipanich, Tawimas, Liu, Gang, Johnson, Evan, Bild, Andrea, Lenburg, Marc E., Ionescu, Diana N., Mayo, John, Yi, Joanne (Eunhee), Tazelaar, Henry, Harmsen, William S., Smith, Judith, Spira, Avrum E., Beane, Jennifer, Limburg, Paul J., Szabo, Eva · 2016 · Cancer Prevention Research
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1940-6207.capr-15-0254

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 35

Metadata

Authors
Lam, S., Mandrekar, S. J., Gesthalter, Y., Allen Ziegler, K. L., Seisler, D. K., Midthun, D. E., Mao, J. T., Aubry, M. C., McWilliams, A., Sin, D. D., Shaipanich, T., Liu, G., Johnson, E., Bild, A., Lenburg, M. E., Ionescu, D. N., Mayo, J., Yi, J. (., Tazelaar, H., Harmsen, W. S., Smith, J., Spira, A. E., Beane, J., Limburg, P. J., & Szabo, E.
Venue
Cancer Prevention Research
Published
2016-12-01
Volume
9
Issue
12
Pages
906-914
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
OpenAlex
W2522736967
Cited by
35
References
1
FWCI
4.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia. https://app.cochat.ai/papers/10.1158/1940-6207.capr-15-0254
The paper
Lam, S., Mandrekar, S. J., Gesthalter, Y., Allen Ziegler, K. L., Seisler, D. K., Midthun, D. E., Mao, J. T., Aubry, M. C., McWilliams, A., Sin, D. D., Shaipanich, T., Liu, G., Johnson, E., Bild, A., Lenburg, M. E., Ionescu, D. N., Mayo, J., Yi, J. (., Tazelaar, H., . . . Szabo, E. (2016). A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-15-0254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.